Sign inCreate account

Report workspace tools

NCT01137786COMPLETEDanonymous

A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Sponsor

Source record

Bracco Diagnostics, Inc

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Non ionic contrast media comparator, Non ionic contrast media comparator

Indication / condition

AI-normalized

Coronary Artery Stenosis

Intervention

Source record

Non ionic contrast media comparator, Non ionic contrast media comparator

Source & freshness

Source record

NCT ID

NCT01137786

Original source

ClinicalTrials.gov

Source last updated

Sep 30, 2013

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01137786

Title

A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Sponsor

Bracco Diagnostics, Inc

Status

COMPLETED

Phase

PHASE4

Condition raw

Coronary Artery Stenosis

Condition normalized

Coronary Artery Stenosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Non ionic contrast media comparator, Non ionic contrast media comparator

Target normalized

Non ionic contrast media comparator, Non ionic contrast media comparator

Interventions

Non ionic contrast media comparator, Non ionic contrast media comparator

Public preview

Source record

This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01137786

Status

COMPLETED

Phase

PHASE4

Sponsor

Bracco Diagnostics, Inc

Executive brief

Investment-Ready Snapshot

This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR. Statistical summaries will be presented to analyse the various laboratory tests for the two groups.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 30, 2013
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01137786

Indication

Coronary Artery Stenosis

Modality

small molecule

Target

Non ionic contrast media comparator, Non ionic contrast media comparator

Intervention

Non ionic contrast media comparator, Non ionic contrast media comparator

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.